What type of study is this?

September 5, 2025Annals of Internal Medicine

In resistant hypertension, amiloride was noninferior to spironolactone for reducing home SBP at 12 wk

View Full Paper

Ask AI

Bookmark

Amiloride reduced home SBP effectively in resistant hypertension, offering a comparable outcome to spironolactone.
Home SBP measurements at 12 weeks indicated noninferiority between the two medications.
This observational analysis assessed the effectiveness of amiloride compared to spironolactone in treating resistant hypertension.
These results may broaden treatment strategies, indicating that amiloride can be a strong alternative to spironolactone.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis showed that amiloride reduced home SBP similarly to spironolactone, suggesting a viable alternative in resistant hypertension treatment.

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Romiti et al. (2025) studied this question.

synapsesocial.com/papers/68bb4d206d6d5674bcd00f35 https://doi.org/10.7326/annals-25-03345-jc

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis showed that amiloride reduced home SBP similarly to spironolactone, suggesting a viable alternative in resistant hypertension treatment.

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

In resistant hypertension, amiloride was noninferior to spironolactone for reducing home SBP at 12 wk

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

In resistant hypertension, amiloride was noninferior to spironolactone for reducing home SBP at 12 wk

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading